Organogenesis Holdings Inc.
Organogenesis Holdings Inc. (ORGO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ORGO · as of Sep 30, 2025
Ownership Breakdown
122
Institutional Holders
▲ 6 vs Q2
$288.65M
Total Inst. Value
▲ $34.54M vs Q2
128.67M
Shares Outstanding
freeFloat 44.59%
68.40M
13F Shares Held
▼ 1.02M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ORGO largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SOLEUS CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 12.13M | 9.56% | 9.56% | $51.20B | Nov 14, 2025 | ▼ 211.7K |
MORGAN STANLEY pharmaceutical preparations | 11.80M | 9.30% | 9.30% | $49.78B | May 27, 2026 | ▼ 259.2K |
FIRST LIGHT ASSET MANAGEMENT, LLC pharmaceutical preparations | 7.50M | 5.91% | 5.91% | $31.64B | Nov 14, 2025 | ▲ 720.7K |
VANGUARD GROUP INC pharmaceutical preparations | 5.04M | 3.97% | 3.97% | $21.25B | Nov 7, 2025 | ▼ 160.8K |
ASSENAGON ASSET MANAGEMENT S.A. pharmaceutical preparations | 4.85M | 3.83% | 3.83% | $20.49B | Oct 7, 2025 | ▲ 2.00M |
BLACKROCK, INC. pharmaceutical preparations | 4.58M | 3.61% | 3.61% | $19.35B | Nov 12, 2025 | ▼ 149.0K |
DEUTSCHE BANK AG\ pharmaceutical preparations | 3.28M | 2.59% | 2.59% | $13.86B | Nov 13, 2025 | ▲ 6.4K |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 2.91M | 2.29% | 2.29% | $12.28B | Nov 12, 2025 | ▼ 195.3K |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 1.75M | 1.38% | 1.38% | $7.39B | Nov 13, 2025 | ▼ 671.1K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.72M | 1.36% | 1.36% | $7.28B | Nov 12, 2025 | ▲ 50.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
18
Increased
+3.33M shares0
New Positions
first time holders26
Decreased
−3.29M shares0
Sold Out
fully exitedNet shares change (top 50)
+40.6K
+3.33M / −3.29M
Net new holders
-8
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ORGO insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
36
Buy transactions
42
Sell transactions
0.86
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Leibowitz Arthur S director | Mar 9, 2026 | Purchase | 5,000 | $2.68 | $13.4K | 291.0K | Form 4 ↗ |
Driscoll Michael Joseph director | Mar 9, 2026 | Purchase | 10,000 | $2.67 | $26.7K | 225.7K | Form 4 ↗ |
Cavorsi Robert Vice President, Strategy | Mar 1, 2026 | Tax Withhold | 700 | $3.21 | $2.2K | 275.5K | Form 4 ↗ |
Montecalvo Antonio S. Vice President, Health Policy | Feb 18, 2026 | Award | 11,330 | — | — | 230.0K | Form 4 ↗ |
Montecalvo Antonio S. Vice President, Health Policy | Feb 18, 2026 | Tax Withhold | 3,778 | $3.84 | $14.5K | 226.2K | Form 4 ↗ |
Gillheeney Gary S. President and CEO | Feb 18, 2026 | Award | 188,856 | — | — | 4.32M | Form 4 ↗ |
Gillheeney Gary S. President and CEO | Feb 18, 2026 | Tax Withhold | 91,311 | $3.84 | $350.6K | 4.23M | Form 4 ↗ |
Grow Brian Chief Commercial Officer | Feb 18, 2026 | Award | 48,818 | — | — | 911.6K | Form 4 ↗ |
Grow Brian Chief Commercial Officer | Feb 18, 2026 | Tax Withhold | 11,887 | $3.84 | $45.6K | 899.7K | Form 4 ↗ |
Bilbo Patrick Chief Operating Officer | Feb 18, 2026 | Award | 49,102 | — | — | 1.14M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Organogenesis Holdings Inc. (ORGO) is primarily owned by institutional investors, who hold approximately 53.2% of total shares outstanding. Company insiders own approximately 55.41%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Organogenesis Holdings Inc. is SOLEUS CAPITAL MANAGEMENT, L.P., holding approximately 12.13 million shares — equal to 9.56% of outstanding shares — as of September 30, 2025.
A total of 122 institutional investors currently hold ORGO stock, with a combined institutional value of approximately $288,654,528 as of the most recent 13F filing period.
Frequently asked questions
ORGO ownershipOrganogenesis Holdings Inc. (ORGO) is primarily owned by institutional investors, who hold approximately 53.2% of shares. The largest shareholder is SOLEUS CAPITAL MANAGEMENT, L.P. with a 9.56% stake. Company insiders hold 55.41%. Data sourced from SEC Form 13F as of September 30, 2025.